<DOC>
	<DOCNO>NCT00075738</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , irinotecan , leucovorin , cisplatin , work different way stop tumor cell divide stop grow die . Giving one chemotherapy drug may kill tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy first-line therapy work treat patient metastatic esophageal cancer .</brief_summary>
	<brief_title>Fluorouracil , Irinotecan , Leucovorin , Cisplatin First-Line Therapy Treating Patients With Metastatic Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient metastatic esophageal cancer treat fluorouracil , irinotecan , leucovorin calcium , cisplatin first-line therapy . Secondary - Determine clinical benefit patient treat regimen . - Determine tolerability regimen patient . - Determine local relapse-free survival patient treat regimen . - Determine overall survival patient treat regimen . OUTLINE : This open-label , multicenter study . Patients receive irinotecan IV 90 minute leucovorin calcium IV 2 hour day 1 . Patients also receive fluorouracil IV continuously 46 hour cisplatin IV 30 minute day 1 2 . Treatment repeat every 15 day 12 course absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : A total 39 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm esophageal cancer Metastatic disease At least 1 unidimensionally measurable metastatic lesion At least 10 mm spiral scanner OR 20 mm sequential scanner Outside field prior radiotherapy No known symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 75 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 1.5 time normal Alkaline phosphatase ≤ 3 time normal ( 5 time normal liver metastasis present ) SGOT SGPT ≤ 3 time normal Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No myocardial infarction within past 6 month No uncontrolled angina Other Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except curatively treat basal cell skin cancer carcinoma situ cervix No illness medical condition would preclude study participation No psychological , social , familial , geographical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 6 month since prior fluorouracil and/or cisplatin No prior chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 6 week since prior radiotherapy Surgery More 4 week since prior surgery Other No concurrent participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
</DOC>